Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation-Reference-Cited by-同舟云学术

Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation

Published:2019-04-08 Issue:4 Volume:106 Page:792-802
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Bergman Arthur¹,Bi Yi‐an²,Mathialagan Sumathy²,Litchfield John³,Kazierad David J.³,Pfefferkorn Jeffrey A.³,Varma Manthena V.S.²^ORCID

Affiliation:

1. Clinical PharmacologyWorldwide Research and DevelopmentPfizer Inc. Groton Connecticut USA

2. Medicine DesignWorldwide Research and DevelopmentPfizer Inc. Groton Connecticut USA

3. Worldwide Research and DevelopmentPfizer Inc. Cambridge Massachusetts USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1419

Reference48 articles.

1. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities.

2. Glucokinase and molecular aspects of liver glycogen metabolism

3. Molecular Physiology of Mammalian Glucokinase

4. Discovery, Structure−Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2R)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675)

5. SAR, Pharmacokinetics, Safety, and Efficacy of Glucokinase Activating 2-(4-Sulfonylphenyl)-N-thiazol-2-ylacetamides: Discovery of PSN-GK1

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay;Clinical Pharmacology & Therapeutics;2024-02-26

2. Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models;Expert Opinion on Drug Metabolism & Toxicology;2024-01-31

3. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

4. Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling;Clinical Pharmacology & Therapeutics;2023-07-13

5. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition–Progress from 2016 to 2023;Drug Metabolism and Disposition;2023-07-05